key: cord-0855948-b7snms9w
authors: Liu, Jing; Zheng, Xiaobin; Huang, Yiying; Shan, Hong; Huang, Jin
title: Successful use of methylprednisolone for treating severe COVID-19
date: 2020-05-29
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.05.021
sha: 393ecc4610c18794ca59b75366497bee50ae5ae9
doc_id: 855948
cord_uid: b7snms9w

Timely and appropriate application of methylprednisolone in severe and critical COVID-19 patients could effectively avoid invasive mechanical ventilation and reduce the mortality.

severe and critical COVID-19 patients could effectively avoid invasive mechanical 27 ventilation and reduce the mortality. 28 29 To the Editor: 30 31 As of April 4, 2020, a total of 1051635 COVID-19 cases had been reported 32 worldwide, among which 56985 deaths occurred (5.42%) 1 . However, to date, no 33 vaccine and no specific antiviral medicine are available to prevent or treat COVID-19 34 infection. A previous study suggested that cytokine release syndrome could be 35 involved in the pathophysiology of severe or critical COVID-19 cases and frequently 36 results in death 2 . Hence, early recognition and effective suppression of the cytokine 37 storm may be life-saving in severe or critical patients. The Fifth Affiliated Hospital of 38 Sun Yat-sen University was the first and, at the time of this report, remains the only 39 designated hospital for management of COVID-19 patients in Zhuhai, China. From 40 January 22 to March 2, we treated 101 COVID-19 patients in total. Though the 41 previously reported fatality rate for severe and critical COVID-19 patients was 42 considerable 2 , those whom we treated all survived. Despite controversies, we think 43 that timely and appropriate application of glucocorticoid plays a crucial role in the 44 treatment of these patients. Herein we introduce our clinical experience with 45 corticosteroid administration in these patients for reference and discussion. 46 47 Methods glucocorticoid application in 15 severe and critical patients (with pulse single-dosage 74 of 40-500mg methylprednisolone according to severity, oxygenation index, speed of 75 progression, production of inflammatory factors, body weight, age, and underlying 76 diseases condition, rather than continuous low-dose glucocorticoid for days ) (Fig. 1,  77 Sup. Tab.2). With this treatment, oxygenation had been improved significantly, and 78 no deaths occurred in these 15 patients. Only one of these 15 patients needed 79 mechanical ventilation for 5 days. When observing pulmonary function during early 80 convalescence phase in COVID-19 patients, we did not find any difference between 81 the two groups with or without glucocorticoid (Sup. Tab.3). We consider that the 82 recovery of lung function in these severe cases received a benefit from using 83 methylprednisolone. Our results also dispelled the worries about the negative impacts 84 of glucocorticoid on virus removal and specific IgG production. The SARS-CoV-2 85 negative-conversion days were 10.0 ± 5.3d and 10.0 ± 7.9d in patients with and 86 without methylprednisolone therapy, respectively, and there was no statistical 87 difference (Sup. Tab.4). Besides, the more severe patients with glucocorticoid therapy 88 produced more specific IgG to SARS-CoV-2 than others (Sup. Tab.5). All patients 89 who received methylprednisolone were examined by pelvic magnetic resonance 90 imaging (MRI) scans before hospital release as screening for femoral head 91 osteonecrosis, and no abnormal results were observed for any patient. No apparent 92 side effect has been observed during a one-month follow-up, probably because of the 93 strictly controlled total dosage of methylprednisolone (the highest dosage of 94 methylprednisolone was 1000mg due to 100kg bodyweight of the patient). 95

The application of glucocorticoid for COVID-19 pneumonia has been controversial, 98 considering the inconclusive clinical evidence and their possible adverse effects. 99

Interim guidance for management of COVID-19 by the World Health Organization 100 (WHO) recommends against routinely giving systemic glucocorticoid 3 . However, it is 101 well known that glucocorticoids are useful for inhibiting the inflammatory storm via 102 suppression of cytokine levels and pro-inflammatory gene expression 4 . 103

Glucocorticoid thus can diminish the serous exudate at the site of inflammation, 104 reduce tissue edema and injury, and relieve symptoms of inflammation. On the other 105 hand, the first report from the autopsy of a COVID-19 patient revealed that severe 106 serous exudate occurred in the lungs, which was in accordance with the decrease in 107 the peripheral blood serum albumin level frequently found in critical patients. 108

Therefore, based on pathological changes of COVID-19 patients, glucocorticoids 109 could be useful in critical cases. In addition, there is no specific effective antiviral 110 medicine for the new coronavirus and no effective therapy available for suppressing 111 the inflammatory storm except glucocorticoid in urgent clinical settings. In our study, 112 we found that timely and appropriate application of glucocorticoid could avoid the 113 

The confirmed COVID-19 patients were determined to be severe or critical according 5 to the "Diagnosis and Treatment of New Coronavirus-Infected Pneumonia" (Sixth 6 trial version) draft by the National Health Commission of China: mild 7 (non-pneumonia), common (mild pneumonia), severe (respiratory rate ≥ 30 8 times/minute, oxygen saturation using a pulse oximeter ≤ 93% at rest, ratio of arterial 9 oxygen partial pressure to fractional inspired oxygen (PaO 2 /FiO 2 ratio) ≤ 300 mmHg), 10 and critical (respiratory failure, septic shock, multiple organ dysfunction or failure 11 requiring an ICU stay). 12

We monitored the patients continuously and assessed the severity at least once per 14 day. Patients would be administrated a dosage of methylprednisolone while 15 presenting one of the following criteria: (1) PaO 2 /FiO 2 ratio ≤ 150 mmHg, (2) 16 respiratory distress does not improve after a short trial of high flow nasal oxygen 17 therapy (duration ≥ 2 hours, gas flow ≥ 50L/min, FiO 2 ≥ 0.6), and (3) multi-lobar 18 infiltrates involving both lungs together with an increase in the size of opacities by ≥ 19 50% within 24-48 hours. Once given an initial dose of methylprednisolone, patients 20 would be assessed more frequently. Repeated implementation of methylprednisolone 21 would be determined when patients met the criteria again.

We determined the dose considering the patient's body weight, underlying conditions, 25 age, severity, oxygenation index, speed of progression, levels of inflammatory 26 biomarkers, body weight. The dosage was individualized for the unique patient. In 27 general, it's about 2-8mg/kg and no more than 500 mg per day. Methylprednisolone 28 was diluted with a 50ml isotonic saline solution and administered intravenously over 29 30 minutes. 30

Results 32 15 out of 26 severe or critical patients met the criteria and received 33 methylprednisolone therapy. After the first dose of methylprednisolone, twelve 34 subjects' oxygenation improved, and nine of them recovered gradually, while three of 35 them suffered a rebound. In these three subjects: patient 1 and patient 2 received 36 another dose methylprednisolone and recovered; patient 5 received second dose 37 methylprednisolone and suffered another rebound after shortly improvement. He then 38 was administrated the third dose medication and recovered. Three remaining subjects 39 continued to deteriorate after receiving the first dose methylprednisolone. Two of 40 them needed another dose, and one needed another two separate doses. The 11 41 remaining severe patients met none of the criteria for methylprednisolone pulse 42 therapy and recovered by supportive care. All of the 26 subjects recovered and had 43 been discharged. The criterion for the decision of methylprednisolone pulse therapy 44 was shown in Supplementary Table 2 

Semi-quantitative scales for seral IgG 64 levels were defined as follows: 0, negative in serum; 1, positive in serum when 1:150 65 dilution; 2, positive in serum when 1:450 dilution; 3, positive in serum when 1:1350 66 dilution; 4, positive in serum when 1:4050 dilution; 5, positive in serum when 67 1:12150 dilution; 6, positive in serum when 1:36450 dilution. The results were shown 68 as median (interquartile range)

CTD (C terminal 70 domain of Nucleocapsid protein of SARS-CoV-2)

RBD：(Receptor binding domain 71 of Spike Glycoprotein of SARS-CoV-2)